Spero Therapeutics, Inc.

NasdaqGS:SPRO Stock Report

Market Cap: US$70.8m

Spero Therapeutics Valuation

Is SPRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SPRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SPRO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SPRO's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SPRO?

Other financial metrics that can be useful for relative valuation.

SPRO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.1x
Enterprise Value/EBITDA0.6x
PEG Ratio0.2x

Price to Earnings Ratio vs Peers

How does SPRO's PE Ratio compare to its peers?

The above table shows the PE ratio for SPRO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22.9x
CTMX CytomX Therapeutics
8x-27.9%US$89.8m
EGRX Eagle Pharmaceuticals
2.2xn/aUS$27.8m
FENC Fennec Pharmaceuticals
45.2x57.4%US$126.4m
VYGR Voyager Therapeutics
36.2x-24.1%US$317.4m
SPRO Spero Therapeutics
4x20.3%US$70.8m

Price-To-Earnings vs Peers: SPRO is good value based on its Price-To-Earnings Ratio (4x) compared to the peer average (22.9x).


Price to Earnings Ratio vs Industry

How does SPRO's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.6%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a28.6%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: SPRO is good value based on its Price-To-Earnings Ratio (4x) compared to the US Biotechs industry average (21.4x).


Price to Earnings Ratio vs Fair Ratio

What is SPRO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SPRO PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4x
Fair PE Ratio15.8x

Price-To-Earnings vs Fair Ratio: SPRO is good value based on its Price-To-Earnings Ratio (4x) compared to the estimated Fair Price-To-Earnings Ratio (15.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SPRO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.29
US$7.50
+481.4%
6.7%US$8.00US$7.00n/a2
Sep ’25US$1.37
US$7.50
+447.4%
6.7%US$8.00US$7.00n/a2
Aug ’25US$1.39
US$7.50
+439.6%
6.7%US$8.00US$7.00n/a2
Jul ’25US$1.28
US$7.50
+485.9%
6.7%US$8.00US$7.00n/a2
Jun ’25US$1.42
US$7.50
+428.2%
6.7%US$8.00US$7.00n/a2
May ’25US$1.55
US$7.50
+385.4%
6.7%US$8.00US$7.00n/a2
Apr ’25US$1.79
US$7.50
+319.0%
6.7%US$8.00US$7.00n/a2
Mar ’25US$1.69
US$7.50
+343.8%
6.7%US$8.00US$7.00n/a2
Feb ’25US$1.57
US$7.50
+377.7%
6.7%US$8.00US$7.00n/a2
Jan ’25US$1.47
US$7.50
+410.2%
6.7%US$8.00US$7.00n/a2
Dec ’24US$1.17
US$7.50
+541.0%
6.7%US$8.00US$7.00n/a2
Nov ’24US$1.14
US$6.67
+484.8%
18.7%US$8.00US$5.00n/a3
Oct ’24US$1.21
US$6.67
+451.0%
18.7%US$8.00US$5.00US$1.313
Sep ’24US$1.52
US$6.67
+338.6%
18.7%US$8.00US$5.00US$1.373
Aug ’24US$1.52
US$6.33
+316.7%
19.7%US$8.00US$5.00US$1.393
Jul ’24US$1.45
US$6.33
+336.8%
19.7%US$8.00US$5.00US$1.283
Jun ’24US$1.80
US$6.33
+251.9%
19.7%US$8.00US$5.00US$1.423
May ’24US$1.85
US$6.33
+242.3%
19.7%US$8.00US$5.00US$1.553
Apr ’24US$1.45
US$6.33
+336.8%
19.7%US$8.00US$5.00US$1.793
Mar ’24US$1.51
US$6.33
+319.4%
19.7%US$8.00US$5.00US$1.693
Feb ’24US$1.88
US$6.33
+236.9%
19.7%US$8.00US$5.00US$1.573
Jan ’24US$1.73
US$6.33
+266.1%
19.7%US$8.00US$5.00US$1.473
Dec ’23US$1.91
US$6.33
+231.6%
19.7%US$8.00US$5.00US$1.173
Nov ’23US$1.97
US$6.33
+221.5%
19.7%US$8.00US$5.00US$1.143
Oct ’23US$2.00
US$6.33
+216.7%
19.7%US$8.00US$5.00US$1.213

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies